Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a
a study on Hepatitis D
Hepatitis Delta Virus Hepatitis D Hepatitis Interferons Ritonavir Interferon-alpha Peginterferon alfa-2a Interferon alpha-2 Lonafarnib PEG IFN-alfa-2a
Lead Scientist at UCSF
- Marina Roytman, Dr.
Health Sciences Clinical Professor, UCSF Marina Roytman, M.D., FACP, is board certified in Internal Medicine and fellowship trained in Medical Education. Her interests include viral hepatitis, drug induced liver injury, autoimmune hepatitis, and medical education. She has won multiple awards for her presentations on hepatitis and drug induced liver injury.
- accepting new patients
- Start Date
- Completion Date
- Eiger BioPharmaceuticals
- Phase 3 Hepatitis D Research Study
- Study Type
- Expecting 400 study participants
- Last Updated